The global market for attention deficit hyperactivity disorder therapeutics is expected to grow from USD 29.56 billion in 2022 to USD 45.68 billion by 2027. The market is expected to increase at a CAGR of 9.09% during the forecast period.
The COVID-19 has had several detrimental consequences for attention deficit hyperactivity disorder (ADHD) patients, and the primary source of the result is sensitivity to the pandemic’s anguish and physical separation measures. The patient’s behavioral difficulties may worsen as a result of these variables. The rise in difficulties will raise sales of ADHD medications, and panic buying by consumers has depleted the existing batch of drugs, forcing manufacturers to produce a new batch. All non-essential medical visits have been postponed, leaving people with ADHD entirely dependent on medications.
Y-O-Y rise in the incidence and prevalence of attention deficit hyperactivity disorder (ADHD) worldwide is majorly driving the expansion of the global ADHD therapeutics market.
Although genetic predisposition is seen in many cases, the reasons for ADHD are yet unknown. According to the Centers for Disease Control and Prevention (CDC), 6.1 million people in the United States were diagnosed with ADHD in 2016, including 388,000 children aged 2–5, 4 million children aged 6–11, and 3 million teenagers aged 12–17. Boys are also more likely to be diagnosed than girls.
The market for ADHD therapies is primarily driven by the negative influence of unstable lifestyles and food additives on children’s diets, which has resulted in an increase in the incidence of ADHD in children aged 4 to 17. Furthermore, rising awareness of the illness among physicians and patients and the lack of routine diagnostic tests are expected to drive revenue growth in the global ADHD market in the coming years.
Furthermore, rising medical developments, a growing number of neuroscience research projects, and increased public awareness about mental illness further contribute to the rise of the market. The global ADHD therapeutics market is also expected to be driven by the biotechnology and pharmaceutical companies focusing more on creating innovative treatments for ADHD. Manufacturers are targeting both youngsters and adults with ADHD. Drugs are developed with various features for children, such as added flavors for ease of intake, but for adults, the focus is on giving a long-lasting effect to prevent taking numerous pills per day. Manufacturers also concentrate on providing items like stimulants and non-stimulants at lower prices. This results in the expansion of the attention-deficit hyperactivity disorder therapeutics market in underserved regions such as APAC and MEA, contributing to the growth of the global ADHD therapeutics market.
On the other hand, contraindications and side effects associated with ADHD medications reduce patients’ quality of life, which is likely to slow revenue growth in the attention-deficit hyperactivity disorder therapeutics market throughout the forecast period. ADHD drugs are associated with contraindications such as allergic reactions to molecules or other medicines and medical conditions such as coronary artery disease, bipolar disorder, blood vessel problems, hypertension, kidney disease, seizures, pancytopenia mydriasis, thrombocytopenic purpura, and visual disturbances. ADHD medications have been linked to side effects such as hallucinations, fast or irregular heartbeat, severe nausea or vomiting, seizure, impotence, numbness, burning, or tingling, decreased appetite, severe headache, upper abdomen, and stomach pain, and weight loss.
A significant number of contraindications and adverse effects associated with ADHD medications are limiting prescriptions depending on a patient’s medical condition, which is predicted to slow revenue development.
Avail sample market brochure of the report to evaluate report usefulness, get a copy @ https://www.marketdataforecast.com/market-reports/attention-deficit-hyperactivity-disorder-therapeutics-market/request-sample
KEY MARKET INSIGHTS:
- Stimulants are projected to become the medications of choice, both among physicians and patients, based on the pharmacological types. During the foreseeable time, amphetamine will also rise in popularity. Stimulants are predicted to lead the global ADHD therapeutics market and increase at a promising rate during the forecast period. Stimulants treat ADHD in around 70-80% of youngsters. Amphetamines, Methylphenidate, Dextroamphetamine, and Dexmethylphenidate are different stimulants. These stimulants aid in the treatment of ADHD. These medications work by stimulating the central nervous system. Concerta (methylphenidate), Dexedrine (amphetamine), and Evekeo are the most often used stimulants (amphetamine).
- In 2021, non-stimulants accounted for the second-largest market share, and with the increase in instances, future growth is predicted to be good. Atomoxetine, Bupropion, and Guanfacine are the three types of non-stimulants. These medications are used to treat ADHD and can be taken with or without stimulants. However, for patients over the age of six, atomoxetine is advised.
- Behavior therapy is the most extensively used strategy for ADHD treatment regarding psychotherapy treatment options. It is a successful treatment that can help children improve their self-esteem, behavior, and self-control. It works best when combined with stimulant medication, and the drug dosage can be gradually reduced over time. Interpersonal psychotherapy is a focused and time-limited mood disorder treatment. It’s becoming increasingly popular, and it’s effective at treating ADHD. Finally, family therapy is a very effective treatment for ADHD that is gaining popularity by the day.
- Among the others, Parent Management Training is the most common. It is highly effective in treating ADHD, and rising awareness of its efficacy will propel its market even further. Treatment for ADHD might also benefit from social skills training provided by schools and professionals. The use of school-based intervention methods to treat ADHD is increasing, and as the number of patients rises, so will the utilization of these methods.
- In 2021, North America accounted for 36% of the global market for ADHD therapeutics. Asia-Pacific is expected to expand at the fastest rate of 12.3% from 2022 to 2027. North America dominates the ADHD therapeutics market with the most significant market share. Due to an increase in the number of people who have attention deficit hyperactivity disorder (ADHD) and rising healthcare expenses. It explains why the United States’ local market has a significant revenue pocket. Throughout the projected period, the region will continue to dominate the global market for attention deficit hyperactivity disorder therapies.
- After new technologies and digital medications, the European attention deficit hyperactivity disorder market is in second place. The industry’s expansion is due to an affluent medical device market and rising healthcare expenditure.
- In the ADHD therapeutics market, the Asia Pacific region is also growing at a healthy CAGR. The unmet demands and large patient population, and the availability of lower-cost ADHD medications have contributed to the market’s rise. Furthermore, the success of pushing up the regional market and growing the healthcare sector is dependent on the region’s economy developing. The rise of the regional market is due to private groups and more significant support from the general public. The ADHD market in the Asia Pacific area is predicted to be driven by the development of healthcare insurance in numerous countries such as Malaysia, Thailand, and Vietnam. In addition, the availability of new medicines and technology influences rising demand and propels the regional ADHD therapeutics market forward.
- With many producers in the industry, the worldwide attention-deficit hyperactivity disorder therapeutics market is hugely fragmented. Pfizer Inc., Novartis AG, Eli Lilly and Company, GlaxoSmithKline PLC, Mallinckrodt Pharmaceuticals, Johnson & Johnson, UCB S.A., Hisamitsu Pharmaceutical Co., Inc., and Purdue Pharma L.P. are among the prominent participants in the global attention-deficit hyperactivity disorder pharmaceuticals market.
The report can be customized as per the requirements; talk to our team @ https://www.marketdataforecast.com/market-reports/attention-deficit-hyperactivity-disorder-therapeutics-market/customization
SEGMENTS COVERED IN THIS REPORT:
Treatment by Medication:
- Stimulants
- Amphetamines
- Methylphenidate
- Dextroamphetamine
- Dexmethylphenidate
- Non-Stimulants
- Atomoxetine
- Bupropion
- Guanfacine
Treatment by Psychotherapy:
- Behaviour Therapy
- Cognitive Behavioral Therapy
- Interpersonal Psychotherapy
- Family Therapy
Treatment by Education or Training:
- Parent Management Training
- Social Skills Training
- School-Based Interventions
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Browse Regional Reports:
- North America ADHD Therapeutics Market
- Europe ADHD Therapeutics Market
- APAC ADHD Therapeutics Market
- Latin America ADHD Therapeutics Market
- MEA ADHD Therapeutics Market
About MarketDataForecast:
Market Data Forecast is a firm working in market research, business intelligence, and consulting. We have rich research and consulting experience for various business domains to cater to individual and corporate clients’ needs.
Contact Us:
Market Data Forecast
Phone: +1-888-702-9626
Email: contact@marketdataforecast.com